Wednesday, July 2, 2025
  • Who’sWho Africa AWARDS
  • About Time Africa Magazine
  • Contact Us
Time Africa Magazine
  • Home
  • Magazine
  • WHO’SWHO AWARDS
  • News
  • World News
    • US
    • UAE
    • Europe
    • UK
    • Israel-Hamas
    • Russia-Ukraine
  • Politics
  • Crime
  • Lifestyle
  • Sports
  • Column
  • Interviews
  • Special Report
No Result
View All Result
Time Africa Magazine
  • Home
  • Magazine
  • WHO’SWHO AWARDS
  • News
  • World News
    • US
    • UAE
    • Europe
    • UK
    • Israel-Hamas
    • Russia-Ukraine
  • Politics
  • Crime
  • Lifestyle
  • Sports
  • Column
  • Interviews
  • Special Report
No Result
View All Result
Time Africa Magazine
No Result
View All Result
  • Home
  • WHO’SWHO AWARDS
  • News
  • Magazine
  • World News

Home » Featured » HIV Vaccine Candidate Prompts Immune Response in Early Human Trials

HIV Vaccine Candidate Prompts Immune Response in Early Human Trials

December 9, 2022
in Featured, Special Report
0
540
SHARES
4.5k
VIEWS
Share on FacebookShare on Twitter

ReadAlso

South Africa’s HIV patients fear losing life-saving treatment due to aid freeze

Ugandan grandmothers fostering HIV-orphaned kids

By Don Rauf

An experimental vaccine designed to prevent HIV (human immunodeficiency virus) has produced promising results in a preliminary study involving a small group of volunteers.

The vaccine candidate showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus.
As detailed December 2 in the journal Science, the treatment produced a broad neutralizing antibody response in 35 of 36 (97 percent) of recipients who received two vaccine doses eight weeks apart.

“With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans,” said William Schief, PhD, a study author and immunologist at Scripps Research, in La Jolla, California, in a press release.

“We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens,” added Dr. Schief, who is also the executive director of vaccine design at the IAVI Neutralizing Antibody Center, which developed the vaccine candidate (called eOD-GT8 60mer).

Schief and his colleagues stress that a preventive HIV vaccine is urgently needed to put an end to the HIV/AIDS epidemic, which began in the early 1980s. Although HIV infections have declined since then because of effective HIV prevention strategies, the World Health Organization (WHO) estimates that 38.4 million people globally were living with HIV by the end of 2021. More than 40 million have died of the virus, which causes AIDS (acquired immunodeficiency syndrome).

Currently, about 1.2 million people in the United States have HIV, and about 13 percent of them don’t know it and need testing, according to HIV.gov. HIV continues to have a disproportionate impact on certain populations, particularly racial and ethnic minorities and gay, bisexual, and other men who have sex with men (MSM).

“The current situation is difficult to sustain,” said Robert Shafer, MD, a professor of medicine at Stanford University in California who specializes in the treatment of infectious diseases.

“If new infections continue at this rate, the pandemic will not be contained,” added Dr. Shafer, underscoring the importance of developing an effective vaccine.

In this current trial, scientists have developed a unique vaccine regimen (referred to as “germ-line targeting”) that, in essence, primes the immune system by inducing rare but powerful antibodies that can neutralize diverse strains of HIV. Known as “broadly neutralizing antibodies,” or bnAbs, these specialized blood proteins could attach to HIV spikes, or proteins on the virus particle surface, that allow the virus to enter human cells, and disable them via important yet difficult-to-access regions that don’t vary much from strain to strain.

Shafer, who is not involved in the study, explained that HIV’s surface protein — called the “envelope” — is shielded by sugar molecules in most places. “There are only a small number of locations on the envelope that can be successfully targeted by neutralizing antibodies that can bind to the envelope and prevent HIV from getting into cells,” he said. “These bnAbs are able to snake their way into the few parts of the envelope that are not shielded by sugar molecules.”

In an editorial response published in Science, Penny Moore, PhD, with the University of the Witwatersrand and the National Institute for Communicable Diseases in South Africa, wrote that a key challenge has been that bnAbs rarely develop, even during infection. “Until now it has not been possible to elicit bnAbs by vaccination,” she wrote.

The vaccine candidate was able to stimulate the B cells, a type of white blood cell that produces antibodies that are precursors to one of the well-known types of bnAb, according to Shafer. “After the first immunization, approximately 1 in 10,000 circulating antibodies was a bnAb precursor,” he said. “After the second immunization at week 8, approximately 1 in 1,000 circulating antibodies was a bnAb precursor.”

The vaccine also had a “favorable safety profile,” creating no significant adverse events.

Further studies involving a larger group of participants is required to prove the effectiveness of the vaccine, says William Schaffner, MD, an infectious-disease specialist and professor of preventive medicine and health policy at the Vanderbilt University School of Medicine in Nashville, Tennessee.

“All they’ve done so far is draw blood and then go to the laboratory to measure the antibodies produced,” says Dr. Schaffner, who was not on the research team. “There have been previous vaccines of various types that look promising in the laboratory but once it got into humans, they weren’t very effective. So the proof will be in the pudding, so to speak. You have to see whether it actually prevents disease, because after all, that’s why the vaccine is being developed.”

The researchers noted that the current study uses a protein-based vaccine model, but they are also working with Moderna to develop an mRNA-based model similar to the platform used for Moderna’s COVID-19 vaccine.

ADVERTISEMENT
Tags: HIVHuman TrialsImmuneVaccine
ADVERTISEMENT
Previous Post

Morocco’s Coach: We want to fly Africa’s flag high just like Senegal, Ghana, Cameroon- we are here to represent Africa

Next Post

U.S. bid for battery metals has Africa blind spot

You MayAlso Like

Column

The Adriana Smith Case Was an Ethical Disaster

June 30, 2025
Agather Atuhaire and Boniface Mwangi addressing a press conference in Nairobi on 2 June. | Photograph: Thomas Mukoya/Reuters
Special Report

We won’t let them get away with this’: Activists to sue Tanzania’s government over ‘sexual torture’

June 29, 2025
Special Report

Pastor Amos Isah Spiritually Manipulated, Seduced My Wife – Former Church Protocol Officer Alleges

June 29, 2025
Iran attacked the largest US base in Qatar on June 23, a day after Trump ordered strikes on Iran’s nuclear sites, despite pledging to stay out of the Israel-Iran war. (AFP)
Column

What the intensifying Israel-Iran conflict says about the future of diplomacy

June 24, 2025
A market in Tougbo, Ivory Coast, last year. The town sits on the front line of Ivory Coast’s fight against Islamist insurgents.
Column

A New Frontline Emerges as Jihadists Eye West Africa Coast

June 24, 2025
Column

Kenneth Okonkwo And His Bitter Politics

June 24, 2025
Next Post

U.S. bid for battery metals has Africa blind spot

America-based woman demands N132.5m refund, says Nigeria ex-gov, Jim Nwobodo 'holding her money hostage' after land deal went awry

Discussion about this post

Finally, Tinubu Reconciles Wike, Fubara

Wike, Fubara Agree On Peace Deal With Tinubu

Goodluck Jonathan Unveils Shocking Truths Behind Nigeria’s Constitutional Crisis During Umaru Musa Yar’Adua’s Prolonged Illness

Are Igbos Cursed Or The Architects Of Their Own Predicament?

I Breastfed My Husband After Giving Birth, It Helped Us Bond — Mother Of Three

A Deep Dive into Allegations of Fraud in Fidelity Bank

  • British government apologizes to Peter Obi, as hired impostors, master manipulators on rampage abroad

    1238 shares
    Share 495 Tweet 310
  • Maids trafficked and sold to wealthy Saudis on black market

    1064 shares
    Share 426 Tweet 266
  • Flight Attendant Sees Late Husband On Plane

    966 shares
    Share 386 Tweet 242
  • ‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

    901 shares
    Share 360 Tweet 225
  • Crisis echoes, fears grow in Amechi Awkunanaw in Enugu State

    735 shares
    Share 294 Tweet 184
  • Trending
  • Comments
  • Latest

British government apologizes to Peter Obi, as hired impostors, master manipulators on rampage abroad

April 13, 2023

Maids trafficked and sold to wealthy Saudis on black market

December 27, 2022
Flight Attendant Sees Late Husband On Plane

Flight Attendant Sees Late Husband On Plane

September 22, 2023
‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

March 21, 2023
Chief Mrs Ebelechukwu, wife of Willie Obiano, former governor of Anambra state

NIGERIA: No, wife of Biafran warlord, Bianca Ojukwu lied – Ebele Obiano:

0

SOUTH AFRICA: TO LEAVE OR NOT TO LEAVE?

0
kelechi iheanacho

TOP SCORER: IHEANACHA

0
Goodluck Ebele Jonathan

WHAT CAN’TBE TAKEN AWAY FROM JONATHAN

0

Most Saint Lucian Formerly Enslaved People Were Nigerians

July 1, 2025

Chief Uchenna Okafor Hosts Commissioner, Reaffirms Clampdown on Illegal Keke, Okada Operators

July 1, 2025

World leaders confront gap between rich and poor at Financing for Development meeting

June 30, 2025

House Committee Issues 48-Hour Ultimatum to Rivers State Sole Administrator Over N24 Billion CCTV Controversy

June 30, 2025

ABOUT US

Time Africa Magazine

TIME AFRICA MAGAZINE is an African Magazine with a culture of excellence; a magazine without peer. Nearly a third of its readers hold advanced degrees and include novelists, … READ MORE >>

SECTIONS

  • Aviation
  • Column
  • Crime
  • Europe
  • Featured
  • Gallery
  • Health
  • Interviews
  • Israel-Hamas
  • Lifestyle
  • Magazine
  • Middle-East
  • News
  • Politics
  • Press Release
  • Russia-Ukraine
  • Science
  • Special Report
  • Sports
  • TV/Radio
  • UAE
  • UK
  • US
  • World News

Useful Links

  • AllAfrica
  • Channel Africa
  • El Khabar
  • The Guardian
  • Cairo Live
  • Le Republicain
  • Magazine: 9771144975608
  • Subscribe to TIME AFRICA biweekly news magazine

    Enjoy handpicked stories from around African continent,
    delivered anywhere in the world

    Subscribe

    • About Time Africa Magazine
    • Privacy Policy
    • Contact Us
    • WHO’SWHO AWARDS

    © 2025 Time Africa Magazine - All Right Reserved. Time Africa is a trademark of Times Associates, registered in the U.S, & Nigeria. Use of this site constitutes acceptance of our Terms of Service.

    No Result
    View All Result
    • WHO’SWHO AWARDS
    • Politics
    • Column
    • Interviews
    • Gallery
    • Lifestyle
    • Special Report
    • Sports
    • TV/Radio
    • Aviation
    • Health
    • Science
    • World News

    © 2025 Time Africa Magazine - All Right Reserved. Time Africa is a trademark of Times Associates, registered in the U.S, & Nigeria. Use of this site constitutes acceptance of our Terms of Service.

    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.